MYM Nutraceuticals Featured in Midas Letter Article
MYM Nutraceuticals Inc. (CSE:MYM) was recently featured in an article by Midas Letter that highlighted several small cap cannabis companies that are well positioned in the sector.
MYM Nutraceuticals Inc. (CSE:MYM) was recently featured in an article by Midas Letter that highlighted several small cap cannabis companies that are well positioned in the sector.
As quoted in the article, MYM Nutraceuticals:
Provided an update regarding their Sublime Culture Inc. ACMPR production facility located in Laval, Quebec. MYM reaffirmed the Sublime Culture ACMPR license application is currently in queue awaiting final review from Health Canada. The company further confirmed it was satisfied that is “has provided Health Canada with all the necessary information in order for them to move ahead with the license application.”
MYM Nutraceuticals had previously submitted a Confirmation of Readiness (COR) for licensing to Health Canada on December 15, 2017. Phase two of the project in Laval would see grow capacity almost quadruple, from 10,000 ft2 to 37,000 ft2.
Turns out, the corporate update was exact panacea MYM Nutraceuticals needed to turn around their stock price.
Click here to read the full article.
Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) for an Investor Presentation.